The current stock price of SRTS is 3.89 USD. In the past month the price increased by 10.8%. In the past year, price decreased by -55.83%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.69 | 214.21B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.92 | 204.25B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.6 | 138.19B | ||
| SYK | STRYKER CORP | 27.16 | 136.80B | ||
| IDXX | IDEXX LABORATORIES INC | 56.56 | 56.95B | ||
| BDX | BECTON DICKINSON AND CO | 13.29 | 54.68B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.07 | 49.32B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.4 | 38.48B | ||
| RMD | RESMED INC | 25.56 | 36.94B | ||
| DXCM | DEXCOM INC | 34.82 | 25.26B | ||
| PODD | INSULET CORP | 66.64 | 21.43B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.44 | 18.34B |
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 35 full-time employees. The company went IPO on 2016-06-03. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
SENSUS HEALTHCARE INC
851 Broken Sound Pkwy NW Ste 215
Boca Raton FLORIDA 33487 US
CEO: Joseph C. Sardano
Employees: 54
Phone: 15619225808
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 35 full-time employees. The company went IPO on 2016-06-03. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
The current stock price of SRTS is 3.89 USD. The price decreased by -0.26% in the last trading session.
SRTS does not pay a dividend.
SRTS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
SENSUS HEALTHCARE INC (SRTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
SENSUS HEALTHCARE INC (SRTS) has a market capitalization of 63.91M USD. This makes SRTS a Micro Cap stock.
SENSUS HEALTHCARE INC (SRTS) will report earnings on 2026-02-03, after the market close.
ChartMill assigns a technical rating of 4 / 10 to SRTS. When comparing the yearly performance of all stocks, SRTS is a bad performer in the overall market: 83.2% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to SRTS. No worries on liquidiy or solvency for SRTS as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months SRTS reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS decreased by -133.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.16% | ||
| ROE | -5.87% | ||
| Debt/Equity | 0 |
9 analysts have analysed SRTS and the average price target is 7.48 USD. This implies a price increase of 92.29% is expected in the next year compared to the current price of 3.89.
For the next year, analysts expect an EPS growth of -187.55% and a revenue growth -21.22% for SRTS